Summary of Utah Project on Exfoliation Syndrome (UPEXS): using a large database to identify systemic comorbidities

Christian James Pompoco 1, Karen Curtin,1,2 Samuel Taylor 1, Chase Paulson,1 Caleb Shumway,3 Matt Conley,1 D James Barker,1 Cole Swiston,1 Brian Stagg 1, Robert Ritch,4 Barbara M Wirostko1

ABSTRACT
The purpose of the Utah Project on Exfoliation Syndrome (UPEXS) is to identify associations between exfoliation syndrome (XFS) and other diseases that share the commonality of abnormalities in elastin and Lysyl Oxidase-Like 1 gene regulation. The UPEXS is unique because it uses the Utah Population Database, which is linked to the Utah genealogy, that contains a compilation of large pedigrees of most families in the state of Utah that go back multiple generations (3 to ≥11). The health and medical records of these family members are linked to vital records and can be used effectively in studies focused on genetic disorders like XFS, where familial clustering of a disorder is a trend. There is increasing evidence that patients with XFS have a higher risk of certain systemic disorders that reflect the systemic tissue abnormalities of XFS. Epidemiological studies focused on patients with XFS have shown that there is an increased risk of these individuals developing other pathologies that have abnormalities in extracellular matrix metabolism and repair. UPEXS has focused on suspected comorbidities that involve abnormalities in elastin maintenance, a protein that plays a role in the makeup of the extracellular matrix. In this paper, the results from the analysis of chronic obstructive pulmonary disease, inguinal hernias, pelvic organ prolapse, obstructive sleep apnoea and atrial fibrillation are summarised along with the utility of using such a large dataset.

BACKGROUND
Exfoliation syndrome (XFS), also known as pseudoexfoliation syndrome, is a systemic age-related disease diagnosed by the deposition of extracellular fibrillar tissue in the eye’s anterior chamber. XFS is the most common form of secondary open-angle glaucoma. This bears great significance considering glaucoma is the leading cause of blindness throughout the world.1 Given the systemic and historical genetic underpinning for XFS to Lysyl Oxidase-Like 1 (LOXL1) risk alleles, the Utah Population Database (UPDB) was used to investigate diseases that a patient diagnosed with XFS might be predisposed to give the belief of an association with elastin, produced by LOXL1.2 The key pathological and clinical finding of XFS is exfoliation material present on a dilated eye examination. Although systemic, ocular findings are pathognomonic and include fibrillar deposits in the anterior chamber, most commonly located on the anterior capsule, lens zonules, and in the iridocorneal angle viewed by gonioscopy. The pupillary margin is also a common location for XFS material. The development of exfoliation glaucoma, iris transillumination defects and cataracts with zonular dehiscence are associated with XFS. Other than ocular involvement, deposited fibrillar material in patients with XFS can also be found in the brain, lungs, heart and skin.3 4

Epidemiology of XFS
The prevalence of XFS varies widely across ethnic groups and geographic regions, highlighting the hypothesised contributing factors such as epigenetics, ultraviolet radiation exposure (UVR) and latitude.5–10 Increased odds of XFS have been shown in geographic regions with increased latitude, which has been hypothesised to be due to an interplay between temperature and greater UVR reflectivity into the eye. Overall, there is a range of XFS prevalence throughout the world.

LOXL1
The LOXL1 gene has been of key interest over the years in trying to understand and elicit the pathophysiology and the risk for XFS. Its enzymatic products act to cross-link and convert tropoelastin to elastin, stabilising and creating functional fibrillar collagens and elastin within the extracellular matrix (ECM).11 12 LOXL1 is a copper-dependent enzyme that has a role in oxidising primary...
Pompoco CJ, et al. BMJ Open Ophth 2021;6:e000803. doi:10.1136/bmjophth-2021-000803

amino substrates to reactive aldehydes. In LOXL1 knockout mice, the observation has been made of an ECM dysregulation, particularly the metabolism of collagen and elastin. Thorleifsson conducted a genome-wide search that showed multiple single-nucleotide polymorphism (SNPs) in a specific region that is associated with exfoliation glaucoma. Two non-synonymous SNPs in the LOXL1 gene explain this association.

Elastin is a crucial component of the ECM, and abnormalities in this protein’s metabolism and production have been linked to the LOXL1 gene. Studies have shown that mice lacking the gene do not produce normal elastic fibres. Other studies focused on elastin abnormalities have shown that altered or enhanced elastin degradation can lead to an increased chance of developing emphysema, atherosclerosis, and cancer. Furthermore, elastin degradation has also been shown to be an effective marker for COPD. Although the LOXL1 knockout mouse may not translate directly to the human clinical pathology, it has directed research towards possible associations between XFS and related systemic pathologies that also involve the ECM and collagen and elastin metabolism.

It is interesting to hypothesise that an epigenetic effect like DNA methylation, caused by one or more environmental triggers, could be leading to these changes of altered ECM as well as LOXL1 and elastin protein expression alterations, such that faulty elastin repair process ensues. Recent research has focused on such epigenetic changes as possibly playing a role in the XFS phenotype. One recent study found that LOXL1 expression is altered via DNA methylation in ocular tissues and blood samples from patients with XFS. Kang et al demonstrated that non-melanoma skin cancer (a marker for UVR) was associated with a higher risk of exfoliation glaucoma. Other studies have demonstrated that UV exposure does lead to changes of DNA methylation in epidermal cells derived from the skin. It is these genetic and epigenetic underpinnings of systemic disease that can be investigated in populations by assessing XFS and elastin dysregulation disorders using large data resources.

**UTAH PROJECT ON EXFOLIATION SYNDROME**

Large databases containing decades of medical history and records of individuals are extremely beneficial in conducting population-based studies as investigators can gather important information about specific clinical phenotypes, environmental influences and disease manifestations that are electronically available for thousands of patients and correlate a phenotype of interest with possible associated comorbidities across a population. The UPDB is a unique representation of such a database, where large amounts of information can be gathered and linked to individuals over their life span. The UPDB contains the medical histories and vital records of over 40 million records that span decades and are linked to an extensive statewide genealogy in which most families in Utah are represented in pedigrees of 3 or more generations. This dataset has enabled identifying genetic phenotypes that have been life-changing in terms of early detection, such as the breast cancer genes BRCA1 and BRCA2.

**Utah Population Database**

The UPDB, housed at the Huntsman Cancer Center at the University of Utah, is a globally unique database that, for nearly 40 years, has enabled epidemiological and outcomes research to be conducted at the Utah population level. Using this resource, pedigrees can be identified with excess clustering of XFS in the Utah population to study familial XFS phenotypes and examine associated comorbidities in both individuals and high-risk XFS families.

For UPEXS, participants’ historical data under an IRB-approved waiver of consent were obtained from the UPDB. We identified 2943 patients diagnosed in Utah with XFS between 1996 and 2015 for our studies and confirmed International Classification of Diseases (ICD) coding accuracy by randomised chart review. Sixty-eight per cent of our individuals with XFS were female, while 32% were male. Approximately 25% of this XFS case population was between 50 and 69, while 75% were between the age of 70 and 90. Over 95% of the population is white. The epidemiological characteristics of this XFS population closely mirror those of the Olmstead Study (Minnesota), which found that XFS incidence increased with age, with a mean age of diagnosis of 73 years, is derived from a population that was 95% white and 76% female. As a comparison cohort, population-based controls with no XFS history in UPDB were randomly selected and matched to XFS on sex, birth year, and follow-up time in Utah in a 5:1 ratio (N=17 413). A diagram of the UPEXS resource, including XFS patient and controls selection and XFS-associated comorbidity cohorts, is shown in figure 1.

**XFS AND ASSOCIATED COMORBIDITIES**

Through the utilisation of the UPDB and the establishment of the Utah Project on Exfoliation Syndrome (UPEXS), we have reported in several manuscripts data that supports the connection of XFS to various elastotic diseases in our Utah population, that is, chronic obstructive pulmonary disease (COPD), inguinal hernias (IHs), pelvic organ prolapse (POP), obstructive sleep apnoea (OSA), and atrial fibrillation (Afib) as associated comorbidities (table 1). We are currently investigating preliminary data of other potential associated comorbidities of XFS that follow a similar trend. These studies are based on the underpinning of the connection of XFS to a comorbid condition via abnormalities of the ECM pathway, deposition and elastin production and or repair. Furthermore, predispositions to XFS and its suspected comorbidities may share environmental mechanisms and
or triggers leading to altered production of LOXL1, and changes in repair, and maintenance of the ECM, as well as the metabolism of elastin and collagen. One common factor that may play a role in the manifestation of these associated systemic comorbidities across our UPEXS patients is a triggering event; an insult and or injury (ie, UV exposure, surgery and or multiple vaginal births), traumatic and or inflammatory (ie, tobacco and inhaled smoke) that then requires the body to start an elastin/ECM repair process that in XFS malfunctions. Our continued UPEXS research shows that patients with XFS are predisposed to various systemic diseases that appear to be associated with elastin and ECM tissue abnormalities consistent with published data.1

### Chronic obstructive pulmonary disease

COPD is the third leading cause of death in the USA, and worldwide is one of the most prevalent chronic, life-threatening pulmonary emphysematous diseases.28 29 COPD occurs at higher rates in men, but in the past two decades, the rate of morbidity and mortality has risen in women.23 Rates of COPD diagnoses have been higher within the white European lineages.30 Changes in pathology consist of ciliary failure, bronchial fibrosis, hypertrophy of connective tissue and smooth muscle in airways, and an increase in deposition of ECM proteins: elastin, collagen and laminin.31–33 One study showed that elastin degradation could lead to an increased chance of developing emphysema.14 Pathological examination of lung tissue shows that samples with emphysematous changes have lower elastin LOXL1 expression and protein levels compared with those without emphysema.34 Furthermore, inhaled smoke appears to be a trigger and or insult resulting in DNA methylation, which may play a role as an environmental trigger.35 36

### UPEXS study design and results for COPD

Two patient cohorts were obtained from the UPDB for a 20-year period (1996–2015): an XFS cohort consisting of 2943 patients and a COPD cohort consisting of 20 589 patients. Both groups were between the age of 50 and

---

**Figure 1** Utah Project on Exfoliation Syndrome (UPEXS) research resource overview. UPDB, Utah Population Database; XFS, exfoliation syndrome.

**Table 1** Utah Project on Exfoliation Syndrome (UPEXS) comorbid phenotypes and XFS, summary of evidence

| Condition                        | Risk of XFS in comorbid cohort vs controls | Risk of comorbid condition in XFS vs XFS controls |
|----------------------------------|------------------------------------------|--------------------------------------------------|
| Atrial fibrillation (AFib)       | 1.2x                                     | 1.2x                                             |
| With history of hypertension     | ↔                                        | ↔                                                |
| Without history of hypertension  | 1.7x                                     | 1.5x                                             |
| Chronic obstructive pulmonary disease (COPD) | ↔                        | 1.4x                                             |
| With tobacco use history         | ↔                                        | 2.2x                                             |
| Inguinal hernia (IH)             | 2.3x                                     | —                                                |
| Direct IH                        | 1.6x                                     | —                                                |
| Indirect IH                      | 12.0x                                    | —                                                |
| Obstructive sleep apnoea (OSA)   | 1.3x                                     | ↔                                                |
| With history of hypertension     | 2.7x                                     | 1.5x                                             |
| Pelvic organ prolapse (POP)      | 1.6x                                     | —                                                |
| Incident XFS (longitudinal study)| 1.5x                                     | —                                                |

An ‘x’ indicates an x-fold increased risk. A dash (−) indicates not investigated. An ↔ indicates no association (95% CI-lower ≥0.8, 95% CI-upper ≤1.2). Bold, p≤0.05; unbold, 0.05<p≤0.10; unbold grey font, p>0.10. XFS, exfoliation syndrome.
90 years at index diagnosis, ICD-9-CM codes were used to determine patients with XFS (365.52, exfoliation glaucoma, and 366.11, exfoliation of the lens capsule) and patients with COPD (COPD, 496.00). A control group of individuals was matched for age and sex to patients with XFS in a 5:1 ratio (N=14 713). A second control group with no history of COPD was randomly selected and matched for age and sex at a 5:1 ratio to patients with COPD (N=1 02 939). The control groups were necessary to have as long a follow-up period as their respective matched patient. In the XFS cohort, we examined the risk of having COPD compared with their matched control group with no history of XFS. Similarly, we examined the risk of having XFS in the COPD group compared with their matched control group with no COPD history.

The characteristics of XFS and patient with COPD cohorts and their matched control groups were examined and compared. In the XFS group, 68.0% were female, while in the COPD group, 43.6% were female. Variables including race, age at diagnosis and follow-up years did not differ greatly between men and women of either patient group. The mean age at the index of diagnosis was 75 years in the patients with XFS and 67 years in the patients with COPD. These ages are consistent with other published data.

OR estimates showed that in the patients with XFS, risk of COPD diagnosis was higher when compared with the non-XFS controls (OR=1.41; 95% CI 1.17 to 1.70; p<0.0004), particularly in a subset of tobacco users (OR=2.17; 95% CI 1.15 to 4.09; p=0.02). Patients with COPD and their respective controls with no COPD did not differ in their risk of a diagnosis of XFS.

Pelvic organ prolapse

POP, including pelvic floor disorders, affects the pelvic connective tissue of postpartum women. According to prevalence estimates, the reported range of symptomatic POP is 3%–11%. Surgical intervention is needed for approximately 11%–19% of women diagnosed with POP. Studies have shown that POP tends to run in families, correlates with elastin defects, and connective tissue repair abnormalities. Studies have also shown that there may be a genetic factor involved with POP. Both disorders may particularly share commonalities of the LOXL1 and elastin pathways. Emerging data regarding DNA methylation of LOXL1 also reveals correlates between POP and XFS, as Zhang et al discovered a statistically significant and differential DNA methylation profile in a series of women with POP compared with controls.

UPEXS study design and results for POP

The study focused on the relationship between POP and XFS and involved a 2-pronged approach using the UPDB. In substudy A, a cross-sectional analysis was done on 132 772 patient records of Utah women who were Medicare recipients for 3 or more years between 1992 and 2009. In substudy B, between 1 January 1995 and 31 December 2014, the longitudinal risk of an incident diagnosis of XFS was analysed of 5130 women between the ages of 30 and 65 years old at baseline, which all have been diagnosed with POP. This cohort was compared with 15 338 females controls that were age-matched and no history of POP. The results of these two studies were consistent with
one another. In substudy A, the mean age of women was 82 years, and it was observed that POP was associated with a 56% increased risk of having a diagnosis of XFS (OR, 1.56; 95% CI 1.4 to 1.7). In the longitudinal analysis of substudy B, the incident risk of having XFS diagnosis was 48% greater in women aged 30–65 years with a diagnosis of POP compared with a control group of females that were age-matched without the diagnosis of POP over 20 years of follow-up (HR, 1.48; 95% CI 1.1 to 1.9). In both studies, the risk of being diagnosed with XFS was higher in women with a prior diagnosis of POP.

Obstructive sleep apnoea

OSA is a sleep disorder characterised by a partial or complete collapse of the upper airways while an individual is asleep, resulting in low airflow to the lungs and subsequent hypoxaemia and hypercapnia. OSA affects people of all ages, but the risk increases with age and obesity. Worldwide, this disorder affects 22% of men and 17% of women. However, some studies suggest the global prevalence of OSA is much higher. The severity of OSA is known to increase with a high BMI, age and male sex. Other risk factors that may play a role in incidence or severity include family history, smoking tobacco, alcohol abuse and menopause. Studies have shown an association between OSA and other systemic diseases such as AFib and hypertension.

UPEXS study design and results for OSA

Using the UPDB, an OSA cohort was identified, consisting of individuals collected over an 18-year period (1999–2017). The OSA cohort consisted of 81 735 patients ages 50 through 90 years of age at the time of index diagnosis based on ICD-9 code 327.23 (OSA), or the ICD-10 code G47.33 beginning in October of 2015. A control group was randomly selected from the UPDB consisting of individuals without a diagnosis of any form of sleep apnoea. This group was individually matched based on age and sex in a 4:1 ratio to the OSA cohort. An XFS cohort of 2943 patients between ages 50 and 90 years diagnosed from 1996 to 2015 was previously identified with ICD-9 codes 365.52 (exfoliation glaucoma) or 366.11 (exfoliation of the lens capsule). A control group used for comparison was gathered with 14 713 subjects, each individually matched to the XFS group for sex and age in a 5:1 ratio. Each control subject was required to have a follow-up appointment in Utah at least as long as their respective matched study patient, based on the latest event recorded in the UPDB.

Conditional multivariable logistic regression models were used to calculate ORs to estimate the risk of XFS in OSA patients compared with their respective control groups. A model that included adjustment for variables such as race, obesity, hypertension, tobacco use, AFib and COPD diagnosis history was also incorporated into the study. First-order interactions were examined between covariates potentially related to both XFS and OSA, including obesity, hypertension, tobacco use, AFib and COPD. The race was incorporated as a binary variable (non-white and white). Obesity was determined via the subjects’ BMI, categorised as non-obese (BMI<30), obese (BMI≥30) or BMI not identified. Hypertension and tobacco use were both recorded as binary variables independent from one another. History of AFib and COPD was determined via ICD-9 codes in the subject’s medical records.

OR estimates for the covariate-adjusted model were done with a 95% CI and p values for the risk of having XFS on OSA patients overall, as well as in OSA patients with a history of hypertension compared with their respective matched control individuals. After accounting for matching variables of sex and age, and confounding variables such as race, obesity, AF, COPD, hypertension and tobacco use, we observed a slightly increased risk of XFS in patients with OSA overall (OR=1.27; 95% CI 1.02 to 1.59; p=0.03).

Atrial fibrillation

AFib is a common arrhythmia characterised by rapid and uncoordinated atrial depolarisation and myocardial contraction, leading to a higher risk of stroke and heart failure. AFib is the most frequent genetically influenced arrhythmia affecting approximately 9% of individuals over the age of 80% and 2% over 65. AFib is a complex disease process involving many structural changes at the atrial myocardium’s cellular level. Specific changes to the atrial myocardium have been observed, including fibrosis, dilation and hypertrophy. It has also been observed in other studies that abnormal levels of specific proteins that influence the ECM lead to disruption of the matrix’s homeostatic state. This disruption is believed to be caused by changes to the metabolic stability of elastin and collagen.

UPEXS study design and preliminary results for AFib

In a preliminary analysis, 2803 patients with XFS between 60 and 90 years old at the disease onset and a set of 43 694 patients diagnosed with AFib were examined. Conditional logistic regression was used to estimate the risk of AFib in patients diagnosed with XFS, compared with respective 5:1 sex-matched and age-matched non-XFS controls. Our pilot data indicate that patients with XFS appear to have a modest 20% increased risk of being diagnosed with AFib (p<0.01). In a preliminary Kaplan-Meier (KM) survival analysis, AFib patients with XFS appeared to survive longer than AFib patients with no history of XFS (p<0.0001). We plan to perform additional subgroup analyses and publish our final results.

UPEXS and survival patterns

In two separate studies, Slettedal et al and Svensson et al observed that individuals with XFS do not appear to have increased mortality and morbidity even when a possibly related life-threatening comorbidity is present. Given the size of this UPDB dataset, and the ability to determine morbidity and mortality in the UPEXS cohort,
time to all-cause and disease-related mortality in the XFS was possible. Our UPEXS dataset included two patient cohorts, those with COPD and AFib, who had diseases known to increase morbidity and mortality, patients with COPD and age-matched control subjects with no history of COPD, stratified by XFS status, were analysed for time to death. KM survival curves were done separately for subjects between ages 50–69 years and subjects who were 70–90 years old at the time of diagnosis to reflect greater mortality risk inherent to the older group. In the age group 50–69 years, non-COPD controls with an XFS diagnosis had the highest survival rate over the 20-year study, with a 10-year survival of 91%. The control group with no XFS had lower survival rates overall, with a 10-year survival at 85%. In contrast, overall survival rates in the COPD group aged from 50 to 69 years were lower compared with their respective control group. However, patients with COPD with a history of XFS history had a not only higher survival rate than patients with COPD with no XFS (10-year survival of 76% and 43%, respectively). A similar trend was present in the 70–90 age group where the patients with XFS without COPD had the highest overall survival (59% at 10 years), followed by the patients without XFS nor COPD (10-year survival of 47%). Having COPD was associated with lower survival, generally, compared with controls. However, patients with COPD with XFS had higher survival rates than patients with COPD without XFS, with 10-year survival rates of 42% and 18%, respectively.

In a subanalysis of patients with COPD who were tobacco users, the survival rate was decreased compared with non-users. Having a medical history of XFS in tobacco-exposed COPD conferred a similar survival advantage. For example, for patients with COPD that use tobacco between the ages of 50–69, the 10-year survival rate of those with XFS was 70%, while the non-XFS subjects had a survival rate of 41%.

**DISCUSSION**

This UPEXS work which used a very large dataset, the UPDB, has helped shed light on various systemic diseases that show an association with XFS. These data from the UPEXS help to support the hypothesis that shared pathogenesis and risk factors may exist as well as a triggering event, such as multiparity in the case of women with POP, tobacco use in COPD, and hypertension, and chronic mechanical stress in AFib patients. It is possible that tissue alterations containing elastin, which are regulated and repaired by enzymes such as *LOXL1* are being affected by these triggering events and impacting disease pathogenesis. There are most likely other triggers and risk factors, perhaps epigenetic and environmental influences, that play a role in these relationships, as has been suggested by others in this field and may indeed involve *LOXL1* as a risk gene. Ultimately the information gained from these UPEXS studies may help reshape our understanding of the role XFS plays in identifying other systemic disorders. Future efforts include an update to the UPEXS to include five additional years of historic data for carefully phenotyped XFS with comprehensive clinical values, comorbid conditions shown or hypothesised to be associated with XFS, as well as information on UV exposure. With this information, predictors of conversion of XFS to exfoliation glaucoma including mild and severe glaucoma outcomes maybe determined thus helping to identify those individuals at greatest risk for vision loss.

In conclusion, additional studies are needed to confirm these UPDB-based results and validate UPEXS results in other populations to continue to elucidate the role XFS plays in associated systemic conditions. Diagnostic coding via the ICD-9 codes can be inaccurate. To address this limitation, we randomly selected 540 medical records on 1901 patients with a diagnosis of XFS from 1996 to 2012 using ICD-9 which confirmed over 90% of our medical records. We are confident that the data presented here, and the current studies being performed using the UPDB population resource will improve our understanding of XFS, its clinical phenotype and associated comorbid diseases. This can help lead to referrals more accurate diagnosis, management, and improvement in earlier identification of diseases associated with XFS and better help identify common risk factors, environmental factors and demographics thus ultimately impacting patients’ outcomes.

**Acknowledgements** We gratefully acknowledge donors to the National Glaucoma Programme of the BrightFocus Foundation for their generous support (award G2020317). We thank the Pediatric and Population Resource of Huntsman Cancer Institute, the University of Utah (funded in part by the Huntsman Cancer Foundation) for its role in the ongoing collection, maintenance and support of the Utah Population Database (UPDB). We also acknowledge partial support for the UPDB through grant P30 CA2014 from the National Cancer Institute, University of Utah, and from the University of Utah’s programme in Personalised Health and Centre for Clinical and Translational Science (CCTS). We also thank the University of Utah CCTS (funded by NIH Clinical and Translational Science Awards), the Pediatric and Population Resource, University of Utah Information Technology Services, and Biomedical Informatics Core for establishing the Master Subject Index between the Utah Population Database, the University of Utah Health Sciences Centre. Research was supported by the NCRP grant, ‘Sharing Statewide Health Data for Genetic Research’ (R01 RR021746, G. Mineau, PI) with additional support from the Utah Department of Health and the University of Utah.

**Contributors** All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: KC, BMW, CJP. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: KC, CShumway, CSwiston, MC, ST, CP, DJB. Critical revision of the manuscript for important intellectual content: KC, BMW, CJP. Statistical analysis: KC. Obtained funding: BMW. Administrative, technical or material support: KC, BMW. Supervision: BS, RR, BMW.

**Funding** Funding for this study was provided by donors of National Glaucoma Research, a programme of the BrightFocus Foundation (Award G2020317) and an unrestricted institutional grant from Research to Prevent Blindness, Inc., New York, New York to the John A Moran Eye Center, University of Utah. Sam Taylor and Chase Paulson received grant support from RUTE (Rural and Underserved Utah Training Experience), a programme to improve healthcare access and longitudinal socioeconomic benefit for underserved communities of Utah, Idaho, Montana and Wyoming. Support for the Utah Population Database was provided by Cancer Center Support Grant from the National Cancer Institute (P30 CA2014), an NCRP grant, ‘Sharing Statewide Health Data for Genetic Research’ (R01 RR021746, G. Mineau, PI) with additional support from the Utah Department of Health and the University of Utah.

**Competing interests** None declared.
REFERENCES
1. Ritch R. Exfoliation syndrome—the most common identifiable cause of open-angle glaucoma. J Glaucoma 1994;3:176–7.
2. Aragon-Martin JA, Ritch R, Liebmann J. Evaluation of LOXL1 gene polymorphisms in exfoliation syndrome and exfoliation glaucoma. Mol Vis 2018;14:533–41.
3. Schlötzer-Schrehardt U, Pasutto F, Sommer P, et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal controls. Invest Ophthalmol Vis Sci 2008;49:380–7.
4. Streten BW, Li ZY, Wallace RN, et al. Pseudoexfoliative fibrilopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 1992;110:1757–62.
5. Greene AG, Evers SB, McDonnell F, et al. Differential lysyl oxidase-like 1 expression in pseudoexfoliation glaucoma is orchestrated via DNA methylation. Exp Eye Res 2020;210:108349.
6. Kang JH, VoPham T, Laden F, et al. Cohort study of nonmelanoma skin cancer and the risk of exfoliation glaucoma. J Glaucoma 2020;29:448–55.
7. Pasquale LR, Jiwhani AZ, Zehavi-Doron I, et al. Solar exposure and residential geographic history in relation to exfoliation syndrome in the United States and Israel. JAMA Ophthalmol 2014;132:1439–45.
8. Zenkel M, Krysta A, Pasutto F, et al. Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 2011;52:8488–95.
9. Lemmelt S, Forsman E, Onkamo P, et al. Association of LOXL1 gene with Finnish exfoliation syndrome patients. J Hum Genet 2009;54:289–97.
10. Konstås AGP, Ringvold A. Epidemiology of exfoliation syndrome. J Glaucoma 2018;27 Suppl 1:S4–11.
11. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007;317:1397–400.
12. Mäki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol 2009;24:651–60.
13. Liu X, Zhao Y, Gao J, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet 2004;36:178–82.
14. Heinz A. Elastases and elastokines: elastin degradation and its significance in health and disease. Crit Rev Biochem Mol Biol 2020;55:252–73.
15. Turino GM, Lin YY, He J, et al. Elastin degradation: an effective biomarker in COPD. COPD 2012;9:435–46.
16. Ye H, Jiang Y, Jing Q, et al. LOXL1 hypermethylation in pseudoexfoliation syndrome in the Uighur population. Invest Ophthalmol Vis Sci 2015;56:S383–43.
17. de Oliveira NFP, de Souza BF, de Castro Coelho M. Uv radiation and its relation to DNA methylation in epidermal cells: a review. Epigenomes 2020;2:23.
18. Prahalad S, Zeft AS, Pimentel R, et al. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum 2010;62:2525–9.
19. Narod SA, Ford GA, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. breast cancer linkage Consortium. Am J Hum Genet 1995;56:254–64.
20. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120–8.
21. The University of Utah Pedigree and Population Resource: Utah Population Database. [Online]. Available: http://healthcare.utah.edu/huntsmancancerinstitute/research/updb/.
22. Karger RA, Jeng SM, Johnson DH, et al. Estimated incidence of pseudoexfoliation syndrome and pseudoexfoliation glaucoma in Olmsted County, Minnesota. J Glaucoma 2003;12:193–7.
23. Taylor SG, Bernhisel AA, Curtin K, et al. Association between chronic obstructive pulmonary disease and exfoliation syndrome: the Utah project on exfoliation syndrome. Ophthalmol Glaucoma 2019;2:3–10.
24. Besch BM, Curtin K, Ritch R, et al. Association of exfoliation syndrome with risk of indirect inguinal hernia: the Utah project on exfoliation syndrome. JAMA Ophthalmol 2018;136:368–74.
25. Rios-Medrano B, Curcio C, Ritch R, et al. Risk for Exfoliation Syndrome in Women With Pelvic Organ Prolapse: A Utah Project on Exfoliation Syndrome (UPESX) Study. JAMA Ophthalmol 2016;134:1255–62.
26. Shumway C, Curtin K, Taylor S, et al. Association between obstructive sleep apnea and exfoliation syndrome: the Utah project on exfoliation syndrome. Ophthalmol Glaucoma 2021;4:260–267.
27. Rios-Medrano B, Curtin K, Taylor SG, et al. Risk of atrial fibrillation is increased in patients with exfoliation syndrome: the Utah project on exfoliation syndrome (UPESX). Acta Ophthalmol 2021. doi:10.1111/aos.15017. [Epub ahead of print: 21 Sep 2021].
28. Kochanek KD, Murphy SL, Xu J. Deaths: final data for 2011. Natl Vital Stat Rep 2015;63:1–120.
29. Xu J, Murphy SL, Kochanek KD, et al. Deaths: final data for 2013. Natl Vital Stat Rep 2016;64:1–119.
30. Gilkes A, Ashworth M, Schofield P, et al. Does COPD risk vary by ethnicity? A retrospective cross-sectional study. Int J Chron Pulm Dis 2016;11:739e746.
31. MacNee W. Pathology, pathogenesis, and pathophysiology. BMJ 2006;332:e1204–02.
32. Karnezis N, Tsilimbaris MK, et al. Association of polycystic ovary syndrome with exfoliation glaucoma: a meta-analysis. Acta Ophthalmol 2015;42:30–7.
33. Karnezis N, Tsilimbaris MK, et al. Association of polycystic ovary syndrome with exfoliation glaucoma: a meta-analysis. Acta Ophthalmol 2015;42:30–7.
34. Konstås AGP, Ringvold A. Epidemiology of exfoliation syndrome. J Glaucoma 2018;27 Suppl 1:S4–11.
35. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007;317:1397–400.
36. Liu X, Zhao Y, Gao J, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet 2004;36:178–82.
37. Heinz A. Elastases and elastokines: elastin degradation and its significance in health and disease. Crit Rev Biochem Mol Biol 2020;55:252–73.
38. Turino GM, Lin YY, He J, et al. Elastin degradation: an effective biomarker in COPD. COPD 2012;9:435–46.
39. Ye H, Jiang Y, Jing Q, et al. LOXL1 hypermethylation in pseudoexfoliation syndrome in the Uighur population. Invest Ophthalmol Vis Sci 2015;56:S383–43.
40. de Oliveira NFP, de Souza BF, de Castro Coelho M. Uv radiation and its relation to DNA methylation in epidermal cells: a review. Epigenomes 2020;2:23.
41. Prahalad S, Zeft AS, Pimentel R, et al. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum 2010;62:2525–9.
42. Narod SA, Ford GA, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. breast cancer linkage Consortium. Am J Hum Genet 1995;56:254–64.
incisional hernia, epigastric hernia, and umbilical hernia. *J Am Coll Surg* 2013;217:289–99.

48 Gong Y, Shao C, Sun Q, et al. Genetic study of indirect inguinal hernia. *J Med Genet* 1994;31:187–92.

49 Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. *Obstet Gynecol* 2014;123:141–8.

50 Liu X, Zhao Y, Pawlyk B, et al. Failure of elastic fiber homeostasis leads to pelvic floor disorders. *Am J Pathol* 2006;168:519–28.

51 Couri BM, Borazjani A, Lenis AT, et al. Validation of genetically matched wild-type strain and lysyl oxidase-like 1 knockout mouse model of pelvic organ prolapse. *Female Pelvic Med Reconstr Surg* 2014;20:287–92.

52 Drewes PG, Yanagisawa H, Starcher B, et al. Pelvic organ prolapse in fibulin-5 knockout mice: pregnancy-induced changes in elastic fiber homeostasis in mouse vagina. *Am J Pathol* 2007;170:578–89.

53 Zhang L, Zheng P, Duan A, et al. Genome-wide DNA methylation analysis of uterosacral ligaments in women with pelvic organ prolapse. *Mol Med Rep* 2019;19:391–9.

54 Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. *Sleep Med Rev* 2017;34:70–81.

55 Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population—a review on the epidemiology of sleep apnea. *J Thorac Dis* 2015;7:1311–20.

56 Stein JD, Pasquale LR, Taiwar N, et al. Geographic and climatic factors associated with exfoliation syndrome. *Arch Ophthalmol* 2011;129:1053–60.

57 Holmqvist F, Guan N, Zhu Z, et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the outcomes Registry for better informed treatment of atrial fibrillation (ORBIT-AF). *Am Heart J* 2015;169:647–54.

58 Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. *Circulation* 2004;110:364–7.

59 Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. *Cardiol Clin* 2009;27:13–24.

60 Polyakova V, Miyagawa S, Szalay Z, et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. *J Cell Mol Med* 2008;12:189–208.

61 Slettedal JK, Sandvik L, Ringvold A. Ocular pseudoexfoliation syndrome and life span. *EBioMedicine* 2015;2:765–9.

62 Svensson R, Ekström C. Pseudoexfoliation and mortality: a population-based 30-year follow-up study. *Acta Ophthalmol* 2015;93:162–4.

63 Jiwani AZ, Pasquale LR, Syndrome E. Exfoliation syndrome and solar exposure: new epidemiological insights into the pathophysiology of the disease. *Int Ophthalmol Clin* 2015;55:13–22.

64 Aung T, Chan AS, Khor C-C. Genetics of exfoliation syndrome. *J Glaucoma* 2018;27 Suppl 1:S12–14.